sábado, 7 de julio de 2018

SANDOZ con Tilray (pioneros) y la marijuana "no cumbustible"


"THIS INDUSTRY HAS ITS SHARE
OF GREAT ANNOUNCEMENTS,
BIG EGOS AND EMPTY PROMISES,
WHEREAS TILRAY HAS HIT ITS MILESTONES QUIETLY,
ONE AT A TIME."
Brendan Kennedy
Tilray’s founder and CEO 



  • -Sandoz Canada and Tilray finalize alliance to provide Canadians with greater access to high-quality, non-combustible medical cannabis options; 
  • -Eight co-branded oil and capsule medical cannabis products are available to the 270,000 Canadian patients using medical cannabis in consultation with their doctors; 
  • -Alliance will conduct research into product innovation and dosing, and enhance healthcare professionals and patient education specifically in the medical cannabis field.
Ver.

Sandoz / Novartis y la marijuana (no "combustible")...




Sandoz Canada today announced that it has finalized its collaboration agreement with Tilray, a Health Canada licensed producer of medical cannabis, allowing Sandoz Canada to become the first Canadian pharmaceutical company to enter the medical cannabis field
The alliance will support the rising interest in medical cannabis1 by providing patients with medical treatment options of stringent manufacturing standards that are adapted to their medical conditions, advocating for broader access to products, and increasing product innovation, research and education.


Eight Sandoz and Tilray co-branded non-combustible medical cannabis products are currently available from Tilray through Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), including cannabis capsules and ingestible oils. Sandoz will not work in the soon-to-be legalized recreational combustible cannabis area.

As a leading patient-focused company, Sandoz Canada is committed to discovering new ways to improve and extend the lives of Canadians by increasing access to life enhancing medications, said Michel Robidoux, President and General Manager, Sandoz Canada. 

As such, we have taken this innovative approach and significant step forward to be the first Canadian pharmaceutical company to support access to medical cannabis for patients and their physicians who have determined that medical cannabis is an effective option for their health conditions.” (Más)

Medical Cannabis in Canada
"In the future, we will be able to leverage Sandoz’s substantial sales force, which is something we could not build up on our own. Furthermore, our collaboration will involve the development of new product formulations.  
Sandoz already has the expertise to develop sprays, patches and many other form factors, and we have started thinking about what will be possible to develop for the Canadian and global market."
Brendan Kennedy
Tilray’s founder and CEO



  Ver también:

USA: FDA aprueba EPIDIOLEX primer cannabinoide
Publicar un comentario